{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:49:07Z","timestamp":1786600147023,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We undertook a statistical modeling study to determine the effect of implementing population\u2010based prostate\u2010specific antigen (PSA) screening in England on overdiagnosis and PSA testing rates in comparison with the current opportunistic testing policy. Our model merged English data on life expectancy, rates of PSA testing and incidence of prostate cancer by stage with epidemiological data on lead time. In the base scenario, introduction of population\u2010based screening led to an approximate 25% reduction in both PSA testing and overdiagnosis in the population compared with the current policy. This was due to the anticipated decrease in PSA testing and overdiagnosis in men aged 70+ years being larger than the projected increase in PSA testing and overdiagnosis in men 50\u201369\u2009years. The overall incidence of early\u2010stage prostate cancer was similar. Population\u2010based screening was found to detect more early\u2010stage cancers that were not overdiagnosed, and is therefore likely to have a greater impact on prostate\u2010cancer mortality than current policy. Findings were robust in sensitivity analyses including an entirely independent modeling approach based on the UK Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP). In conclusion, opportunistic screening policies in England have led to high rates of overdiagnosis and PSA testing. A risk\u2010adapted, population\u2010based prostate cancer screening program would likely reduce the number of PSA tests and overdiagnoses, and increase benefits of PSA testing from reduced prostate\u2010cancer mortality. Population health in England would be improved by adopting an organized PSA screening program and policies to reduce opportunistic PSA testing.<\/jats:p>","DOI":"10.1002\/ijc.70698","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:31:38Z","timestamp":1786339898000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Implementing Population\u2010Based Prostate\u2010Specific Antigen Screening on Testing Rates and Prostate Cancer Overdiagnosis in England: A Statistical Modelling Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-6503","authenticated-orcid":false,"given":"Andrew J.","family":"Vickers","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science University College London  London UK"},{"name":"Department of Urology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6327-4357","authenticated-orcid":false,"given":"Adam R.","family":"Brentnall","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"UK National Screening Committee \u201cProstate Cancer \u201daccessed November 19 2025 https:\/\/view\u2010health\u2010screening\u2010recommendations.service.gov.uk\/prostate\u2010cancer\/."},{"issue":"2","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","DOI":"10.3399\/BJGPO.2024.0040","article-title":"Evaluating Whether Prostate Cancer UK'S Risk Checker Is a Help or Hindrance to Prostate\u2010Specific Antigen Testing Policy: A Mixed\u2010Methods Study","volume":"8","author":"Norori N.","year":"2024","journal-title":"BJGP Open"},{"key":"e_1_2_10_4_1","unstructured":"Guidance \u201cPSA Testing: Advice for Men Without Symptoms \u201daccessed November 19 2025 https:\/\/www.gov.uk\/government\/publications\/prostate\u2010specific\u2010antigen\u2010testing\u2010description\u2010in\u2010brief."},{"key":"e_1_2_10_5_1","unstructured":"\u201cPSA Test. UK NHS \u201daccessed November 19 2025 https:\/\/www.nhs.uk\/tests\u2010and\u2010treatments\/psa\u2010test\/."},{"key":"e_1_2_10_6_1","unstructured":"National Institute for Health and Care Excellence \u201cSuspected Cancer: Recognition and Referral \u201daccessed November 19 2025 https:\/\/www.nice.org.uk\/guidance\/ng12\/resources\/suspected\u2010cancer\u2010recognition\u2010and\u2010referral\u2010pdf\u20101837268071621."},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083800","article-title":"Prostate Specific Antigen Retesting Intervals and Trends in England: Population Based Cohort Study","volume":"391","author":"Collins K. K.","year":"2025","journal-title":"BMJ"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-12-26","article-title":"Empirical Estimates of Prostate Cancer Overdiagnosis by Age and Prostate\u2010Specific Antigen","volume":"12","author":"Vickers A. J.","year":"2014","journal-title":"BMC Medicine"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current Policies on Early Detection of Prostate Cancer Create Overdiagnosis and Inequity With Minimal Benefit","volume":"381","author":"Vickers A.","year":"2023","journal-title":"BMJ"},{"key":"e_1_2_10_10_1","unstructured":"\u201cRapid Cancer Registration Data: Incidence and Treatment Dashboard \u201daccessed November 19 2025 NHS England https:\/\/nhsd\u2010ndrs.shinyapps.io\/rcrd\/."},{"key":"e_1_2_10_11_1","unstructured":"\u201cNational Life Tables: UK \u201daccessed November 19 2025 https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables."},{"key":"e_1_2_10_12_1","unstructured":"\u201cUK Office of National Statistics \u201daccessed November 19 2025 https:\/\/www.ethnicity\u2010facts\u2010figures.service.gov.uk\/uk\u2010population\u2010by\u2010ethnicity\/demographics\/age\u2010groups\/latest\/."},{"issue":"754","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3399\/BJGP.2024.0376","article-title":"Factors Affecting Prostate Cancer Detection Through Asymptomatic Prostate\u2010Specific Antigen Testing in Primary Care in England: Evidence From the 2018 National Cancer Diagnosis Audit","volume":"75","author":"Merriel S. W.","year":"2025","journal-title":"British Journal of General Practice"},{"key":"e_1_2_10_14_1","unstructured":"\u201cNHS England Statistics \u201daccessed November 19 2025 https:\/\/www.england.nhs.uk\/statistics\/statistical\u2010work\u2010areas\/screening\/."},{"issue":"19","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/sim.5750","article-title":"A Note on the Catch\u2010Up Time Method for Estimating Lead or Sojourn Time in Prostate Cancer Screening","volume":"32","author":"Draisma G.","year":"2013","journal-title":"Statistics in Medicine"},{"issue":"12","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123826","article-title":"Prostate Cancer Screening With PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania","volume":"9","author":"Patasius A.","year":"2020","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16\u2010Yr Follow\u2010Up of the European Randomized Study of Screening for Prostate Cancer","volume":"76","author":"Hugosson J.","year":"2019","journal-title":"European Urology"},{"key":"e_1_2_10_18_1","unstructured":"\u201cNHS England Screening \u201daccessed November 19 2025 https:\/\/www.england.nhs.uk\/statistics\/statistical\u2010work\u2010areas\/screening\/."},{"issue":"5","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European Model for an Organised Risk\u2010Stratified Early Detection Programme for Prostate Cancer","volume":"4","author":"Van Poppel H.","year":"2021","journal-title":"European Urology Oncology"},{"issue":"17","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate\u2010Specific Antigen Screening and 15\u2010Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","volume":"331","author":"Martin R. M.","year":"2024","journal-title":"JAMA"},{"key":"e_1_2_10_21_1","unstructured":"Science Media Centre \u201cExpert Reaction to 23 Year Follow Up Data From The European Randomized Study of Screening for Prostate Cancer \u201d(2025) https:\/\/www.sciencemediacentre.org\/expert\u2010reaction\u2010to\u201023\u2010year\u2010follow\u2010up\u2010data\u2010from\u2010the\u2010european\u2010randomized\u2010study\u2010of\u2010screening\u2010for\u2010prostate\u2010cancer."},{"issue":"4","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1370\/afm.1509","article-title":"Physician Communication Regarding Prostate Cancer Screening: Analysis of Unannounced Standardized Patient Visits","volume":"11","author":"Feng B.","year":"2013","journal-title":"Annals of Family Medicine"},{"issue":"1","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2024-000643","article-title":"Geographic, Socioeconomic and Demographic Inequalities in the Incidence of Metastatic Prostate Cancer at Time of Diagnosis in England: A Population\u2010Based Evaluation","volume":"4","author":"Dodkins J.","year":"2025","journal-title":"BMJ Oncology"},{"issue":"6","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jnci\/djp001","article-title":"Lead Time and Overdiagnosis in Prostate\u2010Specific Antigen Screening: Importance of Methods and Context","volume":"101","author":"Draisma G.","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"issue":"1179","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/bjr\/tqaf312","article-title":"Prostate MRI in the United Kingdom: A Survey of Current Practice by the British Society of Urogenital Radiology","volume":"99","author":"Withey S. J.","year":"2026","journal-title":"British Journal of Radiology"},{"issue":"12","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results After Four Years of Screening for Prostate Cancer with PSA and MRI","volume":"391","author":"Hugosson J.","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ijc.70492","article-title":"Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long\u2010Term Follow\u2010Up From the CAP Randomised Trial","volume":"159","author":"Brentnall A. R.","year":"2026","journal-title":"International Journal of Cancer"},{"key":"e_1_2_10_28_1","unstructured":"Prostate Cancer Research \u201cProstate Cancer Screening: The Impact on the NHS \u201daccessed November 19 2025 https:\/\/www.prostate\u2010cancer\u2010research.org.uk\/wp\u2010content\/uploads\/2025\/10\/Prostate\u2010Cancer\u2010Screening\u2010The\u2010Impact\u2010on\u2010the\u2010NHS\u2010Report.pdf."},{"key":"e_1_2_10_29_1","volume-title":"Cost\u2010Effectiveness of Prostate Cancer Screening for Men of Average and High Risk","author":"University of Sheffield School of Medicine and Population Health (SCHARR)","year":"2025"},{"issue":"12","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40273-022-01191-1","article-title":"Cost\u2010Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial","volume":"40","author":"Keeney E.","year":"2022","journal-title":"PharmacoEconomics"},{"issue":"17","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1056\/NEJMe2509793","article-title":"Early Detection of Prostate Cancer \u2010 Time to Fish or Cut Bait","volume":"393","author":"Vickers A.","year":"2025","journal-title":"New England Journal of Medicine"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70698","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70698","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:31:43Z","timestamp":1786339903000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":30,"alternative-id":["10.1002\/ijc.70698"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70698","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]},"assertion":[{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijc.70698"}}